Aviva PLC Purchases 63,622 Shares of DexCom, Inc. (NASDAQ:DXCM)

Aviva PLC boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 35.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 240,902 shares of the medical device company's stock after purchasing an additional 63,622 shares during the quarter. Aviva PLC owned about 0.06% of DexCom worth $18,735,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Versant Capital Management Inc bought a new stake in shares of DexCom in the fourth quarter valued at approximately $25,000. Private Trust Co. NA raised its stake in DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after purchasing an additional 245 shares during the last quarter. TD Private Client Wealth LLC raised its stake in DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after purchasing an additional 167 shares during the last quarter. Larson Financial Group LLC boosted its holdings in DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after purchasing an additional 137 shares during the period. Finally, Heck Capital Advisors LLC acquired a new stake in DexCom in the 4th quarter worth $38,000. Institutional investors and hedge funds own 97.75% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Canaccord Genuity Group increased their target price on shares of DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a research note on Friday, February 14th. Robert W. Baird upgraded DexCom from a "neutral" rating to an "outperform" rating and raised their price objective for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Morgan Stanley boosted their price objective on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Finally, Baird R W raised shares of DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $99.00.

Remove Ads

Insider Activity

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of the firm's stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the sale, the executive vice president now directly owns 83,526 shares in the company, valued at approximately $7,259,244.66. This trade represents a 2.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Jacob Steven Leach sold 2,634 shares of the company's stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the transaction, the chief operating officer now owns 268,644 shares of the company's stock, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 105,009 shares of company stock valued at $8,044,178 in the last quarter. Company insiders own 0.30% of the company's stock.

DexCom Trading Down 1.7 %

Shares of DexCom stock traded down $1.16 during trading on Friday, reaching $66.14. 4,787,867 shares of the company were exchanged, compared to its average volume of 4,195,439. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $139.24. The business has a 50-day moving average price of $76.92 and a 200-day moving average price of $76.68. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $25.93 billion, a price-to-earnings ratio of 46.25, a P/E/G ratio of 2.30 and a beta of 1.50.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Sell-side analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.